{"filing":{"accession_number":"0000096943-26-000101","cik":"0000096943","ticker":"TFX","company_name":"TELEFLEX INC","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"tfx-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/96943/000009694326000101/tfx-20260908.htm"},"events":[{"id":32102,"run_id":29491,"accession_number":"0000096943-26-000101","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Sean M. Salmon was elected and appointed to Teleflex's Board of Directors effective September 8, 2026, with appointment to the Growth and Operating Committee. Salmon brings over 30 years of medical device and pharmaceutical experience, including 21 years at Medtronic as Executive Vice President and President of Cardiovascular, and the Board emphasized his strategic expertise in capital allocation, portfolio strategy, and operational execution.","company_name":"TELEFLEX INC","ticker":"TFX","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35188,"accession_number":"0000096943-26-000101","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the election and appointment of Sean M. Salmon to Teleflex's Board of Directors effective September 8, 2026, with appointment to the Growth and Operating Committee. The principal disclosed action is a person taking a role—a director appointment—not a departure. Salmon's extensive background (30+ years in medical device/pharma, 21 years at Medtronic as EVP/President of Cardiovascular) and the Board's emphasis on his strategic value (\"deep expertise in capital allocation, portfolio strategy and operational execution\") make this material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:01:50.584263+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35189,"accession_number":"0000096943-26-000101","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Sean M. Salmon to Teleflex's Board of Directors, effective September 8, 2026. The press release emphasizes his extensive background as a veteran medical technology executive with over 30 years of experience and more than 20 years at Medtronic in senior leadership roles, including as Executive Vice President and President of Cardiovascular Portfolio. The Board chair's statement highlights his strategic value to the company. This is a material board appointment that would affect a reasonable investor's assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:01:50.584263+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35188,"accession_number":"0000096943-26-000101","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the election and appointment of Sean M. Salmon to Teleflex's Board of Directors effective September 8, 2026, with appointment to the Growth and Operating Committee. The principal disclosed action is a person taking a role—a director appointment—not a departure. Salmon's extensive background (30+ years in medical device/pharma, 21 years at Medtronic as EVP/President of Cardiovascular) and the Board's emphasis on his strategic value (\"deep expertise in capital allocation, portfolio strategy and operational execution\") make this material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:01:50.584263+00:00","company_name":"TELEFLEX INC","ticker":"TFX","filing_date":"2026-09-08"},{"id":35189,"accession_number":"0000096943-26-000101","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Sean M. Salmon to Teleflex's Board of Directors, effective September 8, 2026. The press release emphasizes his extensive background as a veteran medical technology executive with over 30 years of experience and more than 20 years at Medtronic in senior leadership roles, including as Executive Vice President and President of Cardiovascular Portfolio. The Board chair's statement highlights his strategic value to the company. This is a material board appointment that would affect a reasonable investor's assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:01:50.584263+00:00","company_name":"TELEFLEX INC","ticker":"TFX","filing_date":"2026-09-08"}]}